Joseph Monahan - Apr 18, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Apr 18, 2022
Transactions value $
-$488,298
Form type
4
Date filed
4/20/2022, 05:06 PM
Previous filing
Mar 14, 2022
Next filing
Oct 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$488K -30K -22% $16.28 106K Apr 18, 2022 Direct F1, F2
holding ACRS Common Stock 193 Apr 18, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2022.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.